PMID- 26206121
OWN - NLM
STAT- MEDLINE
DCOM- 20161019
LR  - 20181113
IS  - 1661-4917 (Electronic)
IS  - 0004-069X (Print)
IS  - 0004-069X (Linking)
VI  - 64
IP  - 1
DP  - 2016 Feb
TI  - Genetic (KIR, HLA-C) and Some Clinical Parameters Influencing the Level of Liver 
      Enzymes and Early Virologic Response in Patients with Chronic Hepatitis C.
PG  - 65-73
LID - 10.1007/s00005-015-0350-1 [doi]
AB  - Natural killer cells play an important role as effectors of innate immunity and 
      regulators of adaptive immunity. They are important elements of the innate 
      response to viral infections, which they detect using human leukocyte antigen 
      (HLA) class I-binding receptors. Most polymorphic of these are killer cell 
      immunoglobulin-like receptors (KIRs) which exist as two basic isotypes, 
      activating or inhibitory receptors and are encoded by genes distributed 
      differently in unrelated individuals. We searched for links between selected 
      clinical data (including HCV viremia, liver enzymes level and liver histology 
      parameters) and the presence of genes encoding these receptors and their ligands 
      in hepatitis C virus-infected individuals subjected to pegylated interferon-alpha and 
      ribavirin therapy. Genomic DNA samples from two hundred and ninety-two 
      chronically infected patients were typed by polymerase chain reaction for the 
      presence or absence of genes for KIRs and their ligands, class I HLA molecules, 
      and clinical data of the patients were collected. Our results suggest an 
      importance of clinical parameters and the contribution of KIR and HLA genes to 
      the course of hepatitis C virus infection and the response to therapy. The study 
      revealed that levels of liver enzymes before therapy were about 30% higher in 
      patients who possessed a variant KIR2DS4 gene with 22-base pair deletion. 
      Decrease of ALT activity after treatment was higher in HLA-C C2-positive than 
      negative individuals. Beside it, patients demonstrated early virologic response 
      to the therapy if the time lag before treatment was short, particularly in women.
FAU - Mozer-Lisewska, Iwona
AU  - Mozer-Lisewska I
AD  - Chair and Department of Infectious Diseases, Karol Marcinkowski University of 
      Medical Sciences, Poznan, Poland.
FAU - Zwolinska, Katarzyna
AU  - Zwolinska K
AD  - Laboratory of Virology, Department of Immunology of Infectious Diseases, Ludwik 
      Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of 
      Sciences, ul. Rudolfa Weigla 12, 53-114, Wroclaw, Poland. 
      kjzwolinska@iitd.pan.wroc.pl.
FAU - Kowala-Piaskowska, Arleta Elzbieta
AU  - Kowala-Piaskowska AE
AD  - Chair and Department of Infectious Diseases, Karol Marcinkowski University of 
      Medical Sciences, Poznan, Poland.
FAU - Bura, Maciej
AU  - Bura M
AD  - Chair and Department of Infectious Diseases, Karol Marcinkowski University of 
      Medical Sciences, Poznan, Poland.
FAU - Rozplochowski, Blazej
AU  - Rozplochowski B
AD  - Chair and Department of Infectious Diseases, Karol Marcinkowski University of 
      Medical Sciences, Poznan, Poland.
FAU - Pauli, Anna
AU  - Pauli A
AD  - Chair and Department of Infectious Diseases, Karol Marcinkowski University of 
      Medical Sciences, Poznan, Poland.
FAU - Zeromski, Jan
AU  - Zeromski J
AD  - Chair of Clinical Immunology, Karol Marcinkowski University of Medical Sciences, 
      Poznan, Poland.
FAU - Piasecki, Egbert
AU  - Piasecki E
AD  - Laboratory of Virology, Department of Immunology of Infectious Diseases, Ludwik 
      Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of 
      Sciences, ul. Rudolfa Weigla 12, 53-114, Wroclaw, Poland.
FAU - Kusnierczyk, Piotr
AU  - Kusnierczyk P
AD  - Laboratory of Immunogenetics and Tissue Immunology, Ludwik Hirszfeld Institute of 
      Immunology and Experimental Therapy, Polish Academy of Sciences, ul. Rudolfa 
      Weigla 12, 53-114, Wroclaw, Poland. pkusnier@iitd.pan.wroc.pl.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150724
PL  - Poland
TA  - Arch Immunol Ther Exp (Warsz)
JT  - Archivum immunologiae et therapiae experimentalis
JID - 0114365
RN  - 0 (Biomarkers, Pharmacological)
RN  - 0 (HLA-C Antigens)
RN  - 0 (HLA-C*02 antigen)
RN  - 0 (Interferon-alpha)
RN  - 0 (KIR2DS4 protein, human)
RN  - 0 (Receptors, KIR)
RN  - 49717AWG6K (Ribavirin)
SB  - IM
MH  - Adult
MH  - Biomarkers, Pharmacological/metabolism
MH  - Female
MH  - Genetic Association Studies
MH  - Genetic Predisposition to Disease
MH  - HLA-C Antigens/*genetics
MH  - Hepacivirus/drug effects/*physiology
MH  - Hepatitis C, Chronic/*immunology/therapy
MH  - Humans
MH  - Immunity, Innate/drug effects
MH  - Immunotherapy/*methods
MH  - Interferon-alpha/administration & dosage
MH  - Killer Cells, Natural/drug effects/*immunology/virology
MH  - Liver/drug effects/*physiology/virology
MH  - Male
MH  - Middle Aged
MH  - Mutation/*genetics
MH  - Polymorphism, Genetic
MH  - Receptors, KIR/*genetics
MH  - Ribavirin/administration & dosage
PMC - PMC4713718
OTO - NOTNLM
OT  - ALT
OT  - AST
OT  - Early virologic response
OT  - HCV chronic infection
OT  - HLA-C C2
OT  - KIR2DS4
EDAT- 2015/07/25 06:00
MHDA- 2016/11/12 06:00
PMCR- 2015/07/24
CRDT- 2015/07/25 06:00
PHST- 2015/01/22 00:00 [received]
PHST- 2015/04/14 00:00 [accepted]
PHST- 2015/07/25 06:00 [entrez]
PHST- 2015/07/25 06:00 [pubmed]
PHST- 2016/11/12 06:00 [medline]
PHST- 2015/07/24 00:00 [pmc-release]
AID - 10.1007/s00005-015-0350-1 [pii]
AID - 350 [pii]
AID - 10.1007/s00005-015-0350-1 [doi]
PST - ppublish
SO  - Arch Immunol Ther Exp (Warsz). 2016 Feb;64(1):65-73. doi: 
      10.1007/s00005-015-0350-1. Epub 2015 Jul 24.